News
News Center
Academician Wu Zuzhe, known as the "Father of Hematopoietic Stem Cells in China," and his delegation visited Meike for an inspection and study tour.
2020-05-15
On May 14, a delegation of nine members—including Wu Zuzhe, an academician of the Chinese Academy of Sciences and researcher at the Academy of Military Medical Sciences; Dr. Hua Wang from the Institute of Radiation Medicine at the Academy of Military Medical Sciences; Xia Xia, Executive Vice President, and Bi Jianjin, Deputy General Manager, both from Beijing Sanlihe Ze Bio-Technology Co., Ltd.—visited Jiuzhitang Maker’s Daxing production base for an inspection and exchange. They were warmly welcomed and guided through the facility by Liu Chunfeng, Executive Vice President of Jiuzhitang Group; Zhang Quancheng, Chairman of Meike Company; Gao Yansong, CEO; Chen Linjie, Executive Vice President, along with several key technical personnel from the company.
Academician Wu Zuzhe and his delegation first held a symposium and exchange with senior executives and technical experts from Meike Company. Meike CEO Gao Yansong provided an overview of the company and its related research activities. During the discussion, both sides shared insights and exchanged opinions on topics such as stem cell manufacturing processes, quality control methods, and quality systems. They also discussed preclinical research and explored scientific perspectives on the mechanisms of stem cells for specific therapeutic indications.
The scene of the symposium
Venue discussion
After the symposium, Academician Wu Zuzhe and his delegation also toured Meike's factory facilities and laboratories.
Wu Zuzhe is the founder of hematopoietic stem cell research in China and a pioneer in experimental hematology. Over decades of dedicated research into the fundamental theories and clinical applications of hematopoietic stem cells, he successfully performed the world’s first transplant of fetal liver-derived hematopoietic stem cells to treat an acute, severe myeloid radiation patient—whose recipient has now survived for more than 30 years. He was also the first to isolate human-derived hepatocyte growth factor, earning him the title "Father of Hematopoietic Stem Cells in China." Throughout his scientific career spanning over 60 years, Wu Zuzhe has mentored a distinguished group of scientists, including two academicians. His groundbreaking work has earned him more than 10 prestigious awards, such as the National Natural Science Award (Second Class) and the National Science and Technology Progress Award (First Class). In 1999, he received the "Major Contribution Award for Professional Technology" from the Central Military Commission, and in 2000, he was honored with the title "Role Model Teacher of His Generation" by the General Logistics Department. In November 2015, an asteroid—internationally designated as No. 207809—discovered by the Purple Mountain Observatory of the Chinese Academy of Sciences, was permanently named "Wu Zuzhe Star" in his honor.
Beijing Sanliyou Heze Biotechnology Co., Ltd. is an open, technology-transfer platform spearheaded by the team led by Academician Zuze Wu. Established in June 2011, the company is a high-tech enterprise primarily focused on developing biopharmaceutical technologies such as recombinant proteins and regenerative medicine, as well as engaging in new drug research, development, production, and sales. It boasts a 500m² GMP-certified cell preparation facility for clinical applications, along with a state-of-the-art stem cell storage facility.
Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd., established in March 2018, is the exclusive Chinese partner of U.S.-based Stemedica Cell Technologies for stem cell technology. The company has successfully transferred Stemedica’s proprietary Bio-Smart hypoxic stem cell production technology to China and has since established a robust stem cell drug manufacturing system. Currently, Jiuzhitang Maker has meticulously constructed Beijing’s first large-scale allogeneic stem cell R&D and production facility—located in the Beijing Daxing Biomedical Base, known as China’s "Pharmaceutical Valley"—compliant with cGMP standards set by China, the United States, and the European Union. The facility boasts an office and production area spanning 4,500 square meters, featuring four independent B+A clean zones on its production platform. This state-of-the-art infrastructure enables the company to produce clinical-grade stem cell products that meet both Chinese and U.S. regulatory requirements for pharmaceutical submissions.
Related News
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy